Loading...
•
Sep 30, 2021
Adicet Bio Q3 2021 Earnings Report
Reported operational highlights and financial results.
Key Takeaways
Adicet Bio reported its Q3 2021 financial results, highlighting progress in the ADI-001 Phase 1 trial and a new collaboration with Twist Bioscience. The company's net loss was $14.0 million, and it had $192.2 million in cash and cash equivalents.
On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end
Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics and expand pipeline
ADI-001 Phase 1 Clinical Trial Enrolling in Dose Level 2
Entered Collaboration with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
Adicet Bio
Adicet Bio
Forward Guidance
The Company expects that current cash and cash equivalents as of September 30, 2021, will be sufficient to fund its operating expenses through the beginning of the second half of 2023.